NATCO Pharma Limited

1,376.55

INR
+9.60(+0.70%)
As of November 14, 2024 10:00:00 AM

NATCO Pharma Limited Share Price Information

24 hour Low and High

Low: 1373.8
High: 1424.9

All time High

1592.85

Price Change 1h

+₹-14.50 +-1.04%

Price Change 1d

+₹-14.50 +-1.04%

Price Change 1w

+₹-55.00 +-3.84%

NATCO Pharma Limited Market Information

Exchange

NSE

Market Cap

24763.75 Cr

About NATCO Pharma Limited Share

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

4016

CEO

Mr. Rajeev Nannapaneni

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • NATCO Pharma to Seek Acquisition
  • NATCO Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024
  • Are Robust Financials Driving The Recent Rally In NATCO Pharma Limited's (NSE:NATCOPHARM) Stock?
  • Natco Pharma rises nearly 2% after mid-cap firm submits application for Rimegepant Sulfate tablets to US FD...
  • Natco Pharma acquires 40 million shares in eGenesis Inc for USD 8 million

FAQs

NATCO Pharma Limited

1,376.55

INR
+9.60(+0.70%)
As of November 14, 2024 10:00:00 AM

NATCO Pharma Limited Share Price Information

24 hour Low and High

Low: 1373.8
High: 1424.9

All time High

1592.85

Price Change 1h

+₹-14.50 +-1.04%

Price Change 1d

+₹-14.50 +-1.04%

Price Change 1w

+₹-55.00 +-3.84%

NATCO Pharma Limited Market Information

Exchange

NSE

Market Cap

24763.75 Cr

About NATCO Pharma Limited Share

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

4016

CEO

Mr. Rajeev Nannapaneni

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • NATCO Pharma to Seek Acquisition
  • NATCO Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024
  • Are Robust Financials Driving The Recent Rally In NATCO Pharma Limited's (NSE:NATCOPHARM) Stock?
  • Natco Pharma rises nearly 2% after mid-cap firm submits application for Rimegepant Sulfate tablets to US FD...
  • Natco Pharma acquires 40 million shares in eGenesis Inc for USD 8 million

FAQs